3. Fair Value Measurement (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Assets:
Beginning balance at January 1, 2013	$ 5,710,526
Net realized and unrealized gains (losses)
Sale of Investment in TherapeuticsMD	4,605,263
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Member
Assets:
Beginning balance at January 1, 2013	5,710,526
Net realized and unrealized gains (losses)
Included in earnings (in other income)	3,605,263
Included in accumulated other comprehensive income (pre-tax)	(4,710,526)
Sale of Investment in TherapeuticsMD	(4,605,263)
Ending balance at September 30, 2013	0
Liabilities:
Beginning balance at January 1, 2013	14,327,680
Interest accretion of Cypress contingent consideration	505,000
Change in fair value of Cypress contingent consideration	(805,000)
Change in fair value of Cypress put right	6,116,489
Ending balance at September 30, 2013	$ 20,144,169